People with active granulomatosis with polyangiitis (GPA), the most common type of ANCA-associated vasculitis (AAV), had significantly higher levels of a specific type of immune cell called peripheral helper T (Tph) cells in their blood, a study found. Higher levels of circulating Tph (cTph) cells were also significantly linked…
News
Amgen said it declined a U.S. Food and Drug Administration (FDA) request to voluntarily withdraw Tavneos (avacopan), an oral treatment approved for the most common forms of ANCA-associated vasculitis (AAV), from the U.S. market. The FDA made the request because of concerns about the integrity of clinical…
Children with ANCA-associated vasculitis (AAV) have higher numbers of two specific subsets of neutrophils, a type of immune cell implicated in AAV, that produce high levels of molecules linked to inflammation and other damaging processes, a small study showed. Notably, these overactive neutrophils appear to have difficulty processing glutamine,…
Following questions about the integrity of clinical trial data, regulators in Europe are taking a second look at Tavneos (avacopan), an oral therapy approved for ANCA-associated vasculitis (AAV). In a press release, the European Medicines Agency (EMA) announced that it “will now review all available data to…
Rituximab is at least as effective as cyclophosphamide in inducing remission in people with ANCA-associated vasculitis (AAV), and it may offer a safer, more targeted option for many patients, according to a review study. “These findings reinforce the evolving role of rituximab…
Inflammation markers calculated from routine blood tests, such as ratios of different types of immune cells and a combined inflammation index, appear to increase when ANCA-associated vasculitis (AAV) is more active, a study found. Even though these markers are not specific to AAV, they “may serve as potential supportive…
A study linked high levels of a blood protein called CXCL6 with lung disease in people with ANCA-associated vasculitis (AAV), pointing to the protein as a potential biomarker to diagnose the condition and monitor its progression. Data indicate that people with AAV who have inflammatory lung disease tend to…
More than one-third of patients with newly diagnosed eosinophilic granulomatosis with polyangiitis (EGPA) already have serious heart disease, a study found. The research also identified coronary artery spasms, sudden episodes of tightening in the heart’s blood vessels that reduce blood flow and can mimic a heart attack, as…
The first participant with ANCA-associated vasculitis (AAV) has been dosed in a Phase 1 clinical trial testing prulacabtagene leucel (prula-cel, formerly ADI-001), Adicet Bio’s experimental CAR T-cell therapy, in people with autoimmune diseases. All seven disease groups in the Phase 1 trial (NCT06375993) are now actively enrolling participants at…
Tavneos (avacopan), in combination with standard treatment, induced disease remission within six months in nearly all adults with ANCA-associated vasculitis (AAV), according to pooled results from 16 published real-world studies. Real-world remission rates with Tavneos at six months and one year were higher than those reported in the…
Recent Posts
- Even with ANCA vasculitis, we can be awe-struck by our own bodies
- Current adult AAV criteria better at classifying the disease in children
- Nkarta cell therapy trial may soon offer outpatient treatment option in AAV
- The importance of rest in managing vasculitis-related fatigue
- Diagnostic delays in AAV vary by subtype and disease features